Share Name Share Symbol Market Type Share ISIN Share Description
Kuala Innov LSE:KUL London Ordinary Share GG00BRK9BQ81 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 8.25p 0 06:32:19
Bid Price Offer Price High Price Low Price Open Price
0.00p 0.00p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.0 -0.2 -1.3 - 3.46

Kuala Innov (KUL) Latest News

More Kuala Innov News
Kuala Innov Takeover Rumours

Kuala Innov (KUL) Share Charts

1 Year Kuala Innov Chart

1 Year Kuala Innov Chart

1 Month Kuala Innov Chart

1 Month Kuala Innov Chart

Intraday Kuala Innov Chart

Intraday Kuala Innov Chart

Kuala Innov (KUL) Discussions and Chat

Kuala Innov Forums and Chat

Date Time Title Posts
24/11/201514:37KUALA INNOVATIONS LTD – pursuing worldwide investment opportunities780
23/11/201513:08KUALA LIMITED 1.2MILL CAP437
12/1/201509:27Kuala Limited-

Add a New Thread

Kuala Innov (KUL) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Kuala Innov trades in real-time

Kuala Innov (KUL) Top Chat Posts

doodlebug4: Looking forward to tomorrow and the new thread, FastForward Innovations Limited will be up and running asap. I just need to check that the new ticker FFWD and the share price is working properly in the header with the charts.
the stigologist: This is in effect an Investment Trust investing in private unlisted start-up companies the normal discount to NAV would suggest a share price of sub 4p so it will ALWAYS be in BoD interest to dilute whilst the share price is over-inflated
keya5000: Glad he's focussing in the US for the investments, just don't think the UK market place is sharp enough to develop these type of companies (with the odd exception). The interview he did with Money Week (think that was the name with the video) leads me o believe he will be concentrating on embryonic US companies. Given the fast forward book and strategy was started in 2014 (possibly way before) you would have thought he (Mellon) would have been creating the contacts and talking about the deals throughout the previous eighteen months. No doubt he owns several more shares in early stage companies on a private basis and I reckon there are likely already connected entities/stakes that will be reversed onto this when the name change takes place. All looking good and I reckon any raise they do won't be in the millions and won't be detrimental to the prevailing share price at the time, in fact quite the opposite. At the time of the last fund raising the direction and the driving forces behind such had not been known, quite easy to see now what's happening here and say if he raises £500k at 10% discount to the share price you know that cash will soon be deployed into something likely very worthwhile. So whilst I accept a fund raise at some point (it is inevitable) the amounts will I expect be small and only raised when specifically needed. It is also worth considering that he may in effect create a 'directors buy' by exchanging already owned assets with KUL shares. I would expect a none damaging (I.e. Not like YA) type facility could be arranged given the connections. Yes all these options lead to re dilution but we start with such a small number in issue the key to me is to who and how the shares KUL will need to issue are issued to. I don't expect them to go to 'flippers' and create an ever increasing free float of moving ever changing stock.
zangdook: A steady rise is what's called for here, to make sure the share price is well up before any fundraising. The topinfo p&d crowd are the very last people we want. They can trash a share price indefinitely.
tobytime73: Keya not at all. Would you rather i ramp the shares across advfn to push the share price up only for a discounted placing to come and leave investors shafted? this was heavily ramped in June when holders were paying 10p+. How did they feel a few months later when the share price was 5p due to a discounted placing!! keep it real!
doodlebug4: That is true, but the big retraces both happened earlier in the year before these four acquisitions were announced. I can't see the share price retracing as much again, there's too much positive newsflow at the moment and the half year report is due out towards the end of November. I can see where you're coming from, you would like to buy back in at a much lower price - and I would like to top-up at a much lower price, but I don't think it's going to happen!:-)
doodlebug4: I think some people might look at how the share price has performed over the last week or so and think that it has almost doubled without retracing at any point and therefore it should pull back more, but we have already seen a few dips in the price. Also it is worth remembering the fundamental reasons why the price has gone up so noticeably in the first place - two acquisitions in September and two in October so far. The message is gradually filtering through to a wider audience.
hedgehog 100: Keya, As Toby helpfully pointed out yesterday in post 6 above: tobytime73 18 Oct'15 - 11:19 - 6 of 43 1 0 "Here we have two VERY rich investment Gurus with one having his own merchant bank that we could borrow from without having to dilute shareholders." It would make no sense for them to overly dilute themselves at a lowly share price. Instead, KUL can benefit from 'soft loans' to be paid back when equity dilution makes more sense, or when an investment is sold.
hedgehog 100: Thanks DB - excellent work! Remember your near namesake (abbreviated) DBC though!! KUL's 7th. September acquisition of a stake in DBC was acquired for shares from Messrs. Dattels & Mellon (at a deemed value of 5p per KUL share), and was therefore in effect director share buying in KUL by them. 07/09/2015 07:00 UK Regulatory (RNS & others) Kuala Innovations Limited Acquisition "... The Board of Kuala Innovations Limited ("Kuala" or the "Company") is pleased to announce the acquisition of a 4.9 per cent. interest in the issued shares of UK incorporated private company The Diabetic Boot Company Limited ("DBC"). DBC is a private single product medical device company based near Oxford, in the UK. DBC is focussed on the treatment of diabetic foot ulcers ("DFUs"), which are a comorbidity of diabetes mellitus. The treatment of DFUs represents a significant commercial opportunity with the current standard of care and alternative therapies lacking efficacy. DBC's lead product is the PulseFlow(R) which combines intermittent plantar compression with the current standard of care for the treatment of DFUs called offloading. Technology created by DBC in relation to the PulseFlow is currently the subject of a number of granted patents in key jurisdictions, with further patents submitted. Intermittent plantar compression as a mechanism of action has been shown in independent clinical studies to produce statistically significant improvements over placebo in wound closure. ..." "With lead investment from ‘master investor’ Jim Mellon, The Diabetic Boot Company (now Pulse Flow Technologies) successfully raised £1,764,493 to help support the company’s product development and rollout. The Story Every 20 seconds, someone in the world loses a limb to diabetes. Studies show that 50% of those people die within 2 years. Between 2010 - 2011, the NHS spent up to £662 million on ulceration and amputation. The International Diabetes Federation forecasts that the number of diabetics worldwide is likely to reach 552 million by 2030. CEO Les Lindsay, formerly VP of KCI Medical, founded The Diabetic Boot Company (now known as Pulseflow) to solve this problem using innovative biotechnology. The result was 'pulseflow DF' - a patented and clinically proven design capable of healing foot ulcers caused by diabetes within 12 weeks. What’s more, the Armstrong research study showed that the intermittent plantar compression feature utilised in the pulseflow DF resulted in 100% of wounds healed within 12 weeks for compliant patients. Where are they now? The Diabetic Boot Company has received numerous awards, including ‘Start Up Business’ Winner in the 2014 SEHTA Healthcare Business Awards. It was also a runner up for ‘Start Up Business’ in the 2015 Medilink UK Awards, and received a funding grant from Technology Strategy Board. The company was also discussed in the press, most notably in an article by The Telegraph. Investment in this round was led by Jim Mellon, whose most notable investment was UraMin Inc which listed on AIM in 2005 and sold to Areva for £1.6 billion in 2007. You can read more about Jim Mellon in This Is Money, The Telegraph, The FT, FT Advisor and The Sunday Times." HTTP://
hedgehog 100: KUL's 7th. September acquisition of a stake in DBC was acquired for shares from Messrs. Dattels & Mellon, at a deemed value of 5p per KUL share, and was therefore in effect director share buying in KUL by them. KUL also raised £200K. in placings in September at a price of 5p (2 x £100K.). It's nice to be able to buy in at the same price as placees, and even nicer if directors have been increasing their stake at that same price.
Kuala Innov share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20180325 03:28:36